Quantitative flow ratio versus fractional flow reserve for guiding percutaneous coronary intervention: design and rationale of the randomised FAVOR III Europe Japan trial.
Humans
Coronary Angiography
/ methods
Coronary Stenosis
/ diagnostic imaging
Coronary Vessels
Europe
Fractional Flow Reserve, Myocardial
Japan
Myocardial Infarction
Percutaneous Coronary Intervention
Predictive Value of Tests
Prospective Studies
Severity of Illness Index
Randomized Controlled Trials as Topic
Journal
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040
Informations de publication
Date de publication:
03 Apr 2023
03 Apr 2023
Historique:
pmc-release:
03
04
2024
medline:
10
4
2023
pubmed:
18
1
2023
entrez:
17
1
2023
Statut:
epublish
Résumé
Quantitative flow ratio (QFR) is a computation of fractional flow reserve (FFR) based on invasive coronary angiographic images. Calculating QFR is less invasive than measuring FFR and may be associated with lower costs. Current evidence supports the call for an adequately powered randomised comparison of QFR and FFR for the evaluation of intermediate coronary stenosis. The aim of the FAVOR III Europe Japan trial is to investigate if a QFR-based diagnostic strategy yields a non-inferior 12-month clinical outcome compared with a standard FFR-guided strategy in the evaluation of patients with intermediary coronary stenosis. FAVOR III Europe Japan is an investigator-initiated, randomised, clinical outcome, non-inferiority trial scheduled to randomise 2,000 patients with either 1) stable angina pectoris and intermediate coronary stenosis, or 2) indications for functional assessment of at least 1 non-culprit lesion after acute myocardial infarction. Up to 40 international centres will randomise patients to either a QFR-based or a standard FFR-based diagnostic strategy. The primary endpoint of major adverse cardiovascular events is a composite of all-cause mortality, any myocardial infarction, and any unplanned coronary revascularisation at 12 months. QFR could emerge as an adenosine- and wire-free alternative to FFR, making the functional evaluation of intermediary coronary stenosis less invasive and more cost-effective.
Identifiants
pubmed: 36648404
pii: EIJ-D-21-00214
doi: 10.4244/EIJ-D-21-00214
pmc: PMC10068862
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM